Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

ULTRAGENYX PHARMACEUTICAL INC.

(RARE)
  Report
Delayed Nasdaq  -  04:00 2022-11-30 pm EST
36.30 USD   +1.77%
11/29Transcript : Ultragenyx Pharmaceutical Inc. Presents at Piper Sandler 34th Annual Healthcare Conference, Nov-29-2022 10:00 AM
CI
11/22Ultragenyx to Present at Piper Sandler Healthcare Conference
GL
11/22Ultragenyx to Present at Piper Sandler Healthcare Conference
GL
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Days
:
Hours
:
Minutes
:
Seconds
Most relevant news about ULTRAGENYX PHARMACEUTICAL INC.
11/29Transcript : Ultragenyx Pharmaceutical Inc. Presents at Piper Sandler 34th An..
CI
11/22Ultragenyx to Present at Piper Sandler Healthcare Conference
GL
11/22Ultragenyx to Present at Piper Sandler Healthcare Conference
GL
11/21Ultragenyx reports inducement grant under nasdaq listing rule 5635(4)
AQ
11/18Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GL
11/18Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
AQ
11/17Transcript : Ultragenyx Pharmaceutical Inc. Presents at 13th Annual Jefferies..
CI
11/15Transcript : Ultragenyx Pharmaceutical Inc. Presents at Stifel 2022 Healthcar..
CI
11/11Ultragenyx Pharmaceutical Chief Financial Officer Mardi Dier to Depart for Private Biop..
MT
11/10Ultragenyx Announces Departure of Chief Financial Officer
GL
11/10Ultragenyx Pharmaceutical Inc. Announces Departure of Mardi Dier, Executive Vice Presid..
CI
11/10Ultragenyx Pharmaceutical Inc. Announces Departure of Mardi Dier, Chief Financial Offic..
CI
11/09Ultragenyx to Present at Upcoming Healthcare Conferences
GL
11/09Ultragenyx to Present at Upcoming Healthcare Conferences
AQ
11/03Credit Suisse Adjusts Ultragenyx Pharmaceutical's Price Target to $96 From $105, Keeps ..
MT
11/03Baird Upgrades Ultragenyx Pharmaceutical to Outperform From Neutral, Adjusts Price Targ..
MT
11/03Wedbush Lowers Ultragenyx Pharmaceutical's PT to $49 From $51, Says Waiting for Additio..
MT
11/02Transcript : Ultragenyx Pharmaceutical Inc., Q3 2022 Earnings Call, Nov 02, 2..
CI
11/02Ultragenyx : Q3 Earnings Snapshot
AQ
11/02Earnings Flash (RARE) ULTRAGENYX PHARMACEUTICAL Reports Q3 Revenue $90.7M
MT
11/02Ultragenyx Reports Third Quarter 2022 Financial Results and Corporate Update
GL
11/02Ultragenyx Reports Third Quarter 2022 Financial Results and Corporate Update
AQ
11/02Ultragenyx Pharmaceutical Inc. Provides Revenue Guidance for 2022
CI
11/02Ultragenyx Pharmaceutical Inc. Reports Earnings Results for the Third Quarter and Nine ..
CI
10/27Ultragenyx to Host Conference Call for Third Quarter 2022 Financial Results and Corpora..
GL
10/14Insider Sell: Ultragenyx Pharmaceutical
MT
10/13Wedbush Cuts Price Target on Ultragenyx Pharmaceutical to $51 From $68, Maintains Neutr..
MT
10/13Guggenheim Upgrades Ultragenyx Pharmaceutical to Buy From Neutral; Price Target is $50
MT
10/05Ultragenyx reports inducement grant under nasdaq listing rule 5635(4)
AQ
10/04Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GL
10/04Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
AQ
09/12Ultragenyx and Mereo BioPharma to Present Setrusumab Data Update at ASBMR
AQ
09/09Ultragenyx and Mereo BioPharma to Present Setrusumab Data Update at ASBMR
GL
09/09Ultragenyx and Mereo BioPharma to Present Setrusumab Data Update at ASBMR
GL
09/07Transcript : Ultragenyx Pharmaceutical Inc. Presents at Citi's 17th Annual Bi..
CI
09/01Ultragenyx to Participate at Citi BioPharma Conference
GL
09/01Ultragenyx to Participate at Citi BioPharma Conference
AQ
08/23Goldman Sachs Adjusts Price Target on Ultragenyx Pharmaceutical to $74 From $72, Reiter..
MT
08/18Ultragenyx reports inducement grant under nasdaq listing rule 5635(4)
AQ
08/17Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GL
08/17Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
AQ
08/04Ultragenyx reports inducement grant under nasdaq listing rule 5635(4)
AQ
08/03Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GL
08/03Citigroup Adjusts Price Target on Ultragenyx Pharmaceutical to $142 From $146, Reiterat..
MT
08/01Evercore ISI Downgrades Ultragenyx Pharmaceutical to In-Line From Outperform, Adjusts P..
MT
07/29Wedbush Adjusts Price Target on Ultragenyx Pharmaceutical to $68 From $70, Maintains Ne..
MT
07/29Ultragenyx Pharmaceutical : Quarterly Report for Quarter Ending June 30, 2022 (Form 10-Q)
PU
07/29Piper Sandler Adjusts Price Target on Ultragenyx Pharmaceutical to $130 From $135, Keep..
MT
07/28Transcript : Ultragenyx Pharmaceutical Inc., Q2 2022 Earnings Call, Jul 28, 2..
CI
07/28Ultragenyx Pharmaceutical : Reports Second Quarter 2022 Financial Results and Corporate Up..
PU
07/28Ultragenyx Pharmaceutical Posts Wider Q2 Loss, Higher Revenue
MT
07/28Ultragenyx : Q2 Earnings Snapshot
AQ
07/28Ultragenyx Reports Second Quarter 2022 Financial Results and Corporate Update
GL
07/28Earnings Flash (RARE) ULTRAGENYX PHARMACEUTICAL Posts Q2 Revenue $89.3M
MT
07/28Ultragenyx Reports Second Quarter 2022 Financial Results and Corporate Update
GL
07/28Ultragenyx Pharmaceutical Inc. Reports Earnings Results for the Second Quarter and Six ..
CI
07/28Ultragenyx Pharmaceutical Inc. Provides Revenue Guidance for Full Year 2022
CI
07/25Ultragenyx to Host Conference Call for Second Quarter 2022 Financial Results and Corpor..
GL
07/25Ultragenyx to Host Conference Call for Second Quarter 2022 Financial Results and Corpor..
GL
07/21Ultragenyx reports inducement grant under nasdaq listing rule 5635(4)
AQ
07/20Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GL
07/20Investors take a wait-and-see attitude ahead of central bank ..
MS
07/20Analyst recommendations: Alphabet, Amazon, Chevron, Rio Tinto, N..
MS
07/19Goldman Sachs Adjusts Price Target for Ultragenyx Pharmaceutical to $75 From $101, Main..
MT
07/19Ultragenyx Pharmaceutical's Shares Plunge Tuesday Afternoon After Angelman Syndrome Tri..
MT
07/18Transcript : Ultragenyx Pharmaceutical Inc. - Special Call
CI
07/18Ultragenyx Pharma Acquires GeneTx After 'Encouraging' Angelman Syndrome Trial Data
MT
07/18Ultragenyx Pharmaceutical : and GeneTx Provide Program Update on GTX-102 for Angelman Synd..
PU
07/18Ultragenyx Pharmaceutical Acquires GeneTx for $75 Mln Upfront Plus Future Milestone and..
MT
07/18Ultragenyx and GeneTx Provide Program Update on GTX-102 for Angelman Syndrome Including..
GL
07/18Ultragenyx and Genetx Provide Program Update on Gtx-102 for Angelman Syndrome Including..
CI
07/18Ultragenyx Pharmaceutical Inc. acquired GeneTx Biotherapeutics LLC from Foundation for ..
CI
07/15Ultragenyx announces sale of a portion of future north american royalties on crysvita f..
AQ
07/14Wedbush Adjusts Price Target on Ultragenyx Pharmaceutical to $70 From $72, Keeps Neutra..
MT
07/14Ultragenyx Sells 30% of Its Royalties on Crysvita for $500 Million to Canada's Omers
MT
1  2  3  4  5  6  7  8  9  10Next
Upcoming event on ULTRAGENYX PHARMACEUTICAL INC.